Search

Ion Beam Applications

Slēgts

10.54 -1.5

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

10.2

Max

10.8

Galvenie mērījumi

By Trading Economics

Ienākumi

-10M

Pārdošana

206M

P/E

Sektora vidējais

41.111

63.778

Dividenžu ienesīgums

1.56

Peļņas marža

-4.99

Darbinieki

1,943

EBITDA

-372K

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.56%

2.39%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

342M

Iepriekšējā atvēršanas cena

12.04

Iepriekšējā slēgšanas cena

10.54

Ion Beam Applications Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2024. g. 11. sept. 06:28 UTC

Iegādes, apvienošanās, pārņemšana

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.